Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Olfactory Disorder Clear all
Recruiting Not applicable Interventional

Olfactory Training in Mild Cognitive Impairment

NCT06825403
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Olfactory Memory Training, Visual Memory Training
Behavioral
Lead sponsor
Jeffrey Motter
Other
Eligibility
55 Years to 89 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 21, 2026, 11:57 AM EDT
Completed No phase listed Observational Results available

Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects

NCT04431908
View directory record Official record
Conditions
COVID-19
Interventions
olfactory device
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1,320 participants
Timeline
2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00020579
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jul 21, 2026, 11:57 AM EDT
Not listed Not applicable Interventional

"Platelet Rich Plasma for the Management of Post-Viral Olfactory Dysfunction.

NCT05666492
View directory record Official record
Conditions
Olfactory Disorder, Olfaction Disorders
Interventions
Platelet rich plasma, Saline
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 26, 2022 · Synced Jul 21, 2026, 11:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of GLP-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior

NCT07611201
View directory record Official record
Conditions
Obesity, Overweight, Taste Perception, Olfaction, Eating Behavior, Appetite
Interventions
Not listed
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 1 Interventional

Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer

NCT01637194
View directory record Official record
Conditions
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Stage IVA Colon Cancer, Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Colon Cancer, Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Tongue Cancer
Interventions
everolimus, cetuximab, pharmacological study, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Jul 21, 2026, 11:57 AM EDT
Not listed Phase 2 Interventional

Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders

NCT06434818
View directory record Official record
Conditions
Substance Use Disorders, Opioid Use Disorder, Alcohol Use Disorder, Cocaine Use Disorder, Methamphetamine-dependence
Interventions
EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance), CBOT with olfactory stimulants & OFC tasks, CBOT Sham
Combination Product
Lead sponsor
Evon Medics LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Jul 21, 2026, 11:57 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluate a Medication on How Hunger and Appetite Are Influenced by Smell

NCT01021176
View directory record Official record
Conditions
Food Intake
Interventions
Placebo spray, Diltiazem
Other · Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Jul 21, 2026, 11:57 AM EDT
Completed No phase listed Observational

Olfactory Dysfunction of Rhinosinusitis - Cyclic Adenosine Monophosphate (cAMP)/Calcium Signaling Study

NCT00970190
View directory record Official record
Conditions
Sinusitis
Interventions
Not listed
Lead sponsor
Greg Davis
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Not applicable Interventional

Visual-OLfactory Training in Participants With COVID-19 Resultant Loss of Smell

NCT04710394
View directory record Official record
Conditions
Anosmia, Covid19, Ageusia, Hyposmia, Hypogeusia, SARS-CoV-2 Infection, COVID-19 Pandemic
Interventions
Smell Training
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 1 Interventional

SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck

NCT00005647
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
paclitaxel, semaxanib
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 9, 2010 · Synced Jul 21, 2026, 11:57 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)

NCT05855369
View directory record Official record
Conditions
Smell Dysfunction, Olfactory Disorder, Long COVID
Interventions
Trigeminal Nerve Stimulation (TNS), Active Smell Training (ST), Placebo Smell Training (PBO)
Device · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 21, 2026, 11:57 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Investigating the Efficacy of OMT to Recover Olfactory Perception After COVID-19

NCT06766279
View directory record Official record
Conditions
Anosmia
Interventions
Osteopathic Manipulative Treatment, Sham treatment
Procedure
Lead sponsor
Burrell College of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Las Cruces, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00014456
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Smell on Mood and Physical Responses

NCT00097253
View directory record Official record
Conditions
Stress, Anxiety, Depression
Interventions
Exposure to relaxant and stimulant odors
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 44 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2010 · Synced Jul 21, 2026, 11:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Individual Variations of Taste and Smell Perception in Alcohol Use Disorder (AUD)

NCT05677321
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Not listed
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
475 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Steroid Nasal Irrigation for Flavor Evaluation and Detection Study

NCT02985515
View directory record Official record
Conditions
Olfactory Disorder
Interventions
Smell training
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Jul 21, 2026, 11:57 AM EDT
Not listed Phase 1Phase 2 Interventional

Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2

NCT04846010
View directory record Official record
Conditions
Sequelae of; Infection, Post Infection Glomerulonephritis, Post-Infectious Peripheral Neuralgia, Post-Infectious Disorder (Disorder), Post-Infectious Arthritis, Post-Infectious Polyneuritis, Post-Infectious Parkinsonism, Post-Infectious Hypothyroidism, Post Infectious Osteoarthritis, Anxiety Disorders, Depression, Depression, Anxiety, Depression, Bipolar, Insomnia, GERD, Gastro Esophageal Reflux, Hepatitis, Glomerulonephritis
Interventions
PurWet, FurFat, PurApo, PurPhl, PurClo, PurInf, Smoliv
Combination Product
Lead sponsor
All Natural Medicine Clinic, LLC
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Jul 21, 2026, 11:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Taste Perception and Chronic Disease Risk

NCT01023906
View directory record Official record
Conditions
Cardiovascular Disease, Diabetes, Obesity, Metabolic Syndrome, Aging
Interventions
Not listed
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 1 Interventional

Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function

NCT00002901
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chemosensory Dysfunction and Recovery in Endoscopic Endonasal Skull Base Surgery

NCT05912881
View directory record Official record
Conditions
Anosmia, Skull Base Neoplasms
Interventions
Olfactory training, Placebo training
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV

NCT03937869
View directory record Official record
Conditions
Bacterial Vaginoses
Interventions
Secnidazole
Drug
Lead sponsor
Lupin Research Inc
Industry
Eligibility
12 Years to 17 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
Long Beach, California • Hialeah, Florida • Miami Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Results available

Helping Olfaction and Nutrition On Renal Replacement

NCT02479451
View directory record Official record
Conditions
End Stage Renal Disease, Olfactory Disorders
Interventions
Theophylline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Jul 21, 2026, 11:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Expectation on Natural and Drug -Induced Rewards

NCT01036230
View directory record Official record
Conditions
Drug Abuse
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Jul 21, 2026, 11:57 AM EDT